Regenerative Medicine and Stem Cells Technologies

Flat brains growing on microscope slides may have revealed a new wrinkle in the story of how the brain folds.

Much as a frame provides structural support for a house and the chassis provides strength and shape for a car, a team of Penn State engineers believe they have a way to create the structural framework for growing living tissue using an off-the-shelf 3-D printer.

Regulatory T (Treg) cells are key regulators of immune tolerance and are capable of suppressing multiple immune cell types and blocking excessive inflammatory responses. Although roles for tissue-resident Foxp3+ Treg cells in maintaining non-lymphoid tissue homeostasis have been suggested, evidence of a relationship between tissue-specific stem cells and Treg cells remains sparse

A baby has been born after becoming the longest-frozen embryo after being cryopreserved for 24 years.

U.S. health officials on Tuesday approved the nations first gene therapy for an inherited disease, a treatment that improves the sight of patients with a rare form of blindness. It marks another major advance for the emerging field of genetic medicine.

Recent advances in self-organizing, 3-dimensional tissue cultures of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) provided an in vitro model that recapitulates many aspects of the in vivo developmental steps. Using Rax-GFP-expressing ESCs, newly generated Six3−/− iPSCs, and conditional null Six3delta/f;Rax-Cre ESCs, we identified Six3 repression of R-spondin 2 (Rspo2) as a required step during optic vesicle morphogenesis and neuroretina differentiation.

Houston Methodist neuroscientist Robert Krencik, Ph.D., and his team have developed a new system to reduce the time it takes to grow these brain models, which will give them the ability to screen drugs and study whats behind disease-causing mutations more quickly.

The World in 2018, the annual publication from The Economist, predicts that 2018 will be a nerve-jangling year as people across the world attempt to escape the tensions of politics and the frenzies of technology.

ViaCyte picked up $10 million to fund the clinical development of its stem cell-derived treatment for patients who have Type 1 diabetes and are at risk of complications.

Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, functional heart tissues for human therapy are lacking.